Chronic Kidney Disease(CKD)
Conditions
Keywords
Sedentary
Brief summary
RESET-CKD is evaluating an intervention to support Black adults with chronic kidney disease (CKD) to reduce their sedentary (e.g., sitting) time. Half of the participants will be randomized to the intervention, where the goal is to support individuals to reduce their sitting time, and the other half will be randomized to an attention control condition that provides CKD-related education not related to sedentary behavior. All participants will be followed for 12 weeks.
Interventions
BEHAVIORALRESET-CKD
RESET-CKD is a 12-week intervention that consists of four major components to support decreasing sedentary behavior: (1) health coaching, (2) feedback charts on sedentary behavior, (3) a workbook, and (4) reminders and cues.
OTHERAttention Control
CKD-related education
Sponsors
University of Illinois at Chicago
National Institute of Nursing Research (NINR)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Self-identifies as Black or African American * Age ≥35 to ≤80 years old * CKD Stage 1-4 * Self-reported 6 or more hours/day of sedentary time * Ability to speak/read/understand English * Has access to a telephone
Exclusion criteria
* Being unable to walk 1 block * Being unable to stand from a seated position without assistance * Using a wheelchair, walker, or cane for all of their ambulation * Presence of a condition(s) or diagnosis, either physical or psychological, that precludes participation, including: Lower-extremity amputation (AKA or BKA) without prosthetic, Orthopedic condition that would preclude prompted sit-to-stand transitions or standing, Neurologic or psychiatric condition that would preclude prompted sit-to- stand transitions or standing, Severe cognitive impairment, Unstable coronary artery disease (i.e., angina with activity), Orthostatic hypotension * Kidney transplant * Any other condition that the investigator considers precludes participation in the trial * Participated in the Patient Advisory Board
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in sedentary time | Baseline to week 12 | Change in activPAL-measured sedentary time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in self-reported sedentary time | Baseline to week 12 | Change in self-reported sedentary time |
| Change in health-related quality of life | Baseline to week 12 | Change in health-related quality of life measured via the KDQOL |
Countries
United States
Outcome results
None listed